 | • レポートコード：GIR201101529 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、152ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、良性前立腺肥大症（BPH）治療薬の世界市場を調査対象にし、良性前立腺肥大症（BPH）治療薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（5-α-レダクターゼ阻害剤、ベータ遮断薬、植物薬、漢方薬）、用途別分析（病院薬局、小売薬局、オンライン薬局）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：Astellas Pharma、Valeant Pharmaceuticals、Sanofi、Eli Lilly、Bristol-Myers Squibb、GlaxoSmithKline、Foresee Pharmaceuticals、Bayer HealthCare、ADC Therapeutics、Endo Pharmaceuticals、Urologixs、BHR Pharma、Merck、Sanpower Group、Agennix、Teva Pharmaceutical Industries、Novartis、Boehringer Ingelheim、ANI Pharmaceuticals、Advaxis、Spectrum Pharmaceuticals、Eisai、Nymox Pharmaceutical、Madrigal Pharmaceuticals、LIDDS、Ferring、Takeda Pharmaceuticals、IO THERAPEUTICS ・メーカー別販売量、売上、市場シェア ・良性前立腺肥大症（BPH）治療薬の地域別市場分析 ・良性前立腺肥大症（BPH）治療薬の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・良性前立腺肥大症（BPH）治療薬のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・良性前立腺肥大症（BPH）治療薬のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・良性前立腺肥大症（BPH）治療薬の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・良性前立腺肥大症（BPH）治療薬の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・良性前立腺肥大症（BPH）治療薬の種類別市場規模2015-2020：5-α-レダクターゼ阻害剤、ベータ遮断薬、植物薬、漢方薬 ・良性前立腺肥大症（BPH）治療薬の用途別市場規模2015-2020：病院薬局、小売薬局、オンライン薬局 ・良性前立腺肥大症（BPH）治療薬の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Benign Prostatic Hyperplasia (BPH) Medication market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Benign Prostatic Hyperplasia (BPH) Medication market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Benign Prostatic Hyperplasia (BPH) Medication market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Benign Prostatic Hyperplasia (BPH) Medication market has been segmented into
5-Alpha-Reductase Inhibitors
Beta-Blockers
Botanicals and Traditional Chinese Medicine
By Application, Benign Prostatic Hyperplasia (BPH) Medication has been segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Benign Prostatic Hyperplasia (BPH) Medication market presented in the report. This section sheds light on the sales growth of different regional and country-level Benign Prostatic Hyperplasia (BPH) Medication markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Benign Prostatic Hyperplasia (BPH) Medication market.
The report offers in-depth assessment of the growth and other aspects of the Benign Prostatic Hyperplasia (BPH) Medication market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Benign Prostatic Hyperplasia (BPH) Medication Market Share Analysis
Benign Prostatic Hyperplasia (BPH) Medication competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Benign Prostatic Hyperplasia (BPH) Medication sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Benign Prostatic Hyperplasia (BPH) Medication sales, revenue and market share for each player covered in this report.
The major players covered in Benign Prostatic Hyperplasia (BPH) Medication are:
Astellas Pharma
Valeant Pharmaceuticals
Sanofi
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
Foresee Pharmaceuticals
Bayer HealthCare
ADC Therapeutics
Endo Pharmaceuticals
Urologixs
BHR Pharma
Merck
Sanpower Group
Agennix
Teva Pharmaceutical Industries
Novartis
Boehringer Ingelheim
ANI Pharmaceuticals
Advaxis
Spectrum Pharmaceuticals
Eisai
Nymox Pharmaceutical
Madrigal Pharmaceuticals
LIDDS
Ferring
Takeda Pharmaceuticals
IO THERAPEUTICS
Among other players domestic and global, Benign Prostatic Hyperplasia (BPH) Medication market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Benign Prostatic Hyperplasia (BPH) Medication product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Benign Prostatic Hyperplasia (BPH) Medication, with price, sales, revenue and global market share of Benign Prostatic Hyperplasia (BPH) Medication in 2018 and 2019.
Chapter 3, the Benign Prostatic Hyperplasia (BPH) Medication competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Benign Prostatic Hyperplasia (BPH) Medication breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Benign Prostatic Hyperplasia (BPH) Medication market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Benign Prostatic Hyperplasia (BPH) Medication sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Medication Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 5-Alpha-Reductase Inhibitors
1.2.3 Beta-Blockers
1.2.4 Botanicals and Traditional Chinese Medicine
1.3 Market Analysis by Application
1.3.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Overview of Global Benign Prostatic Hyperplasia (BPH) Medication Market
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Astellas Pharma
2.1.1 Astellas Pharma Details
2.1.2 Astellas Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Astellas Pharma SWOT Analysis
2.1.4 Astellas Pharma Product and Services
2.1.5 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Valeant Pharmaceuticals
2.2.1 Valeant Pharmaceuticals Details
2.2.2 Valeant Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Valeant Pharmaceuticals SWOT Analysis
2.2.4 Valeant Pharmaceuticals Product and Services
2.2.5 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Sanofi SWOT Analysis
2.3.4 Sanofi Product and Services
2.3.5 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Eli Lilly SWOT Analysis
2.4.4 Eli Lilly Product and Services
2.4.5 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Bristol-Myers Squibb SWOT Analysis
2.5.4 Bristol-Myers Squibb Product and Services
2.5.5 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 GlaxoSmithKline
2.6.1 GlaxoSmithKline Details
2.6.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 GlaxoSmithKline SWOT Analysis
2.6.4 GlaxoSmithKline Product and Services
2.6.5 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Foresee Pharmaceuticals
2.7.1 Foresee Pharmaceuticals Details
2.7.2 Foresee Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Foresee Pharmaceuticals SWOT Analysis
2.7.4 Foresee Pharmaceuticals Product and Services
2.7.5 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Bayer HealthCare
2.8.1 Bayer HealthCare Details
2.8.2 Bayer HealthCare Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Bayer HealthCare SWOT Analysis
2.8.4 Bayer HealthCare Product and Services
2.8.5 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 ADC Therapeutics
2.9.1 ADC Therapeutics Details
2.9.2 ADC Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 ADC Therapeutics SWOT Analysis
2.9.4 ADC Therapeutics Product and Services
2.9.5 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Endo Pharmaceuticals
2.10.1 Endo Pharmaceuticals Details
2.10.2 Endo Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Endo Pharmaceuticals SWOT Analysis
2.10.4 Endo Pharmaceuticals Product and Services
2.10.5 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Urologixs
2.11.1 Urologixs Details
2.11.2 Urologixs Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Urologixs SWOT Analysis
2.11.4 Urologixs Product and Services
2.11.5 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 BHR Pharma
2.12.1 BHR Pharma Details
2.12.2 BHR Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 BHR Pharma SWOT Analysis
2.12.4 BHR Pharma Product and Services
2.12.5 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 Merck
2.13.1 Merck Details
2.13.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Merck SWOT Analysis
2.13.4 Merck Product and Services
2.13.5 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 Sanpower Group
2.14.1 Sanpower Group Details
2.14.2 Sanpower Group Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Sanpower Group SWOT Analysis
2.14.4 Sanpower Group Product and Services
2.14.5 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.15 Agennix
2.15.1 Agennix Details
2.15.2 Agennix Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Agennix SWOT Analysis
2.15.4 Agennix Product and Services
2.15.5 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.16 Teva Pharmaceutical Industries
2.16.1 Teva Pharmaceutical Industries Details
2.16.2 Teva Pharmaceutical Industries Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Teva Pharmaceutical Industries SWOT Analysis
2.16.4 Teva Pharmaceutical Industries Product and Services
2.16.5 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.17 Novartis
2.17.1 Novartis Details
2.17.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Novartis SWOT Analysis
2.17.4 Novartis Product and Services
2.17.5 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.18 Boehringer Ingelheim
2.18.1 Boehringer Ingelheim Details
2.18.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Boehringer Ingelheim SWOT Analysis
2.18.4 Boehringer Ingelheim Product and Services
2.18.5 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.19 ANI Pharmaceuticals
2.19.1 ANI Pharmaceuticals Details
2.19.2 ANI Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 ANI Pharmaceuticals SWOT Analysis
2.19.4 ANI Pharmaceuticals Product and Services
2.19.5 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.20 Advaxis
2.20.1 Advaxis Details
2.20.2 Advaxis Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 Advaxis SWOT Analysis
2.20.4 Advaxis Product and Services
2.20.5 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.21 Spectrum Pharmaceuticals
2.21.1 Spectrum Pharmaceuticals Details
2.21.2 Spectrum Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.21.3 Spectrum Pharmaceuticals SWOT Analysis
2.21.4 Spectrum Pharmaceuticals Product and Services
2.21.5 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.22 Eisai
2.22.1 Eisai Details
2.22.2 Eisai Major Business and Total Revenue (Financial Highlights) Analysis
2.22.3 Eisai SWOT Analysis
2.22.4 Eisai Product and Services
2.22.5 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.23 Nymox Pharmaceutical
2.23.1 Nymox Pharmaceutical Details
2.23.2 Nymox Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.23.3 Nymox Pharmaceutical SWOT Analysis
2.23.4 Nymox Pharmaceutical Product and Services
2.23.5 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.24 Madrigal Pharmaceuticals
2.24.1 Madrigal Pharmaceuticals Details
2.24.2 Madrigal Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.24.3 Madrigal Pharmaceuticals SWOT Analysis
2.24.4 Madrigal Pharmaceuticals Product and Services
2.24.5 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.25 LIDDS
2.25.1 LIDDS Details
2.25.2 LIDDS Major Business and Total Revenue (Financial Highlights) Analysis
2.25.3 LIDDS SWOT Analysis
2.25.4 LIDDS Product and Services
2.25.5 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.26 Ferring
2.26.1 Ferring Details
2.26.2 Ferring Major Business and Total Revenue (Financial Highlights) Analysis
2.26.3 Ferring SWOT Analysis
2.26.4 Ferring Product and Services
2.26.5 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.27 Takeda Pharmaceuticals
2.27.1 Takeda Pharmaceuticals Details
2.27.2 Takeda Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.27.3 Takeda Pharmaceuticals SWOT Analysis
2.27.4 Takeda Pharmaceuticals Product and Services
2.27.5 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.28 IO THERAPEUTICS
2.28.1 IO THERAPEUTICS Details
2.28.2 IO THERAPEUTICS Major Business and Total Revenue (Financial Highlights) Analysis
2.28.3 IO THERAPEUTICS SWOT Analysis
2.28.4 IO THERAPEUTICS Product and Services
2.28.5 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Benign Prostatic Hyperplasia (BPH) Medication Manufacturer Market Share in 2019
3.3.2 Top 6 Benign Prostatic Hyperplasia (BPH) Medication Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Regions
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Regions (2015-2020)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Regions (2015-2020)
4.2 North America Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
4.3 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
4.5 South America Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Country
5.1.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Country (2015-2020)
5.1.2 North America Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Country (2015-2020)
5.2 United States Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
5.3 Canada Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
5.4 Mexico Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Country
6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Country (2015-2020)
6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Country (2015-2020)
6.2 Germany Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6.3 UK Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6.4 France Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6.5 Russia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6.6 Italy Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Regions (2015-2020)
7.2 China Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.3 Japan Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.4 Korea Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.5 India Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.7 Australia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Country
8.1.1 South America Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Country (2015-2020)
8.1.2 South America Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Country (2015-2020)
8.2 Brazil Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
8.3 Argentina Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
9.3 Turkey Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
9.4 Egypt Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
9.5 South Africa Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Type (2015-2020)
10.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Type (2015-2020)
10.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2015-2020)
11 Global Benign Prostatic Hyperplasia (BPH) Medication Market Segment by Application
11.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
11.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2015-2020)
11.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Application (2015-2020)
12 Market Forecast
12.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Growth Rate (2021-2025)
12.2 Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Regions (2021-2025)
12.2.1 North America Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.2.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.2.4 South America Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.2.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.3 Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Type (2021-2025)
12.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Type (2021-2025)
12.3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Share Forecast by Type (2021-2025)
12.4 Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Application (2021-2025)
12.4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Application (2021-2025)
12.4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Benign Prostatic Hyperplasia (BPH) Medication by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 8. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 9. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 10. Astellas Pharma SWOT Analysis
Table 11. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 12. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Valeant Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 14. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 15. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 16. Valeant Pharmaceuticals SWOT Analysis
Table 17. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 18. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Sanofi Basic Information, Manufacturing Base and Competitors
Table 20. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 21. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 22. Sanofi SWOT Analysis
Table 23. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 24. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 26. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 27. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 28. Eli Lilly SWOT Analysis
Table 29. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 30. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 32. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 33. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 34. Bristol-Myers Squibb SWOT Analysis
Table 35. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 36. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 38. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 39. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 40. GlaxoSmithKline SWOT Analysis
Table 41. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 42. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Foresee Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 45. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 46. Foresee Pharmaceuticals SWOT Analysis
Table 47. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 48. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Bayer HealthCare Basic Information, Manufacturing Base and Competitors
Table 50. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 51. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 52. Bayer HealthCare SWOT Analysis
Table 53. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 54. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. ADC Therapeutics Basic Information, Manufacturing Base and Competitors
Table 56. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 57. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 58. ADC Therapeutics SWOT Analysis
Table 59. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 60. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Endo Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 62. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 63. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 64. Endo Pharmaceuticals SWOT Analysis
Table 65. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 66. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Urologixs Basic Information, Manufacturing Base and Competitors
Table 68. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 69. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 70. Urologixs SWOT Analysis
Table 71. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 72. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. BHR Pharma Basic Information, Manufacturing Base and Competitors
Table 74. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 75. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 76. BHR Pharma SWOT Analysis
Table 77. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 78. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. Merck Basic Information, Manufacturing Base and Competitors
Table 80. Merck Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 81. Merck Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 82. Merck SWOT Analysis
Table 83. Merck Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 84. Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. Sanpower Group Basic Information, Manufacturing Base and Competitors
Table 86. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 87. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 88. Sanpower Group SWOT Analysis
Table 89. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 90. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 91. Agennix Basic Information, Manufacturing Base and Competitors
Table 92. Agennix Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 93. Agennix Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 94. Agennix SWOT Analysis
Table 95. Agennix Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 96. Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 97. Teva Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 98. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 99. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 100. Teva Pharmaceutical Industries SWOT Analysis
Table 101. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 102. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 103. Novartis Basic Information, Manufacturing Base and Competitors
Table 104. Novartis Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 105. Novartis Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 106. Novartis SWOT Analysis
Table 107. Novartis Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 108. Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 109. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Type and Application
Table 110. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 111. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 112. Boehringer Ingelheim SWOT Analysis
Table 113. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 114. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 115. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 116. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 117. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 118. ANI Pharmaceuticals SWOT Analysis
Table 119. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 120. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 121. Advaxis Basic Information, Manufacturing Base and Competitors
Table 122. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 123. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 124. Advaxis SWOT Analysis
Table 125. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 126. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 127. Spectrum Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 128. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 129. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 130. Spectrum Pharmaceuticals SWOT Analysis
Table 131. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 132. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 133. Eisai Basic Information, Manufacturing Base and Competitors
Table 134. Eisai Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 135. Eisai Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 136. Eisai SWOT Analysis
Table 137. Eisai Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 138. Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 139. Nymox Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 140. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 141. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 142. Nymox Pharmaceutical SWOT Analysis
Table 143. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 144. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 145. Madrigal Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 146. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 147. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 148. Madrigal Pharmaceuticals SWOT Analysis
Table 149. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 150. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 151. LIDDS Basic Information, Manufacturing Base and Competitors
Table 152. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 153. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 154. LIDDS SWOT Analysis
Table 155. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 156. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 157. Ferring Basic Information, Manufacturing Base and Competitors
Table 158. Ferring Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 159. Ferring Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 160. Ferring SWOT Analysis
Table 161. Ferring Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 162. Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 163. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 164. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 165. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 166. Takeda Pharmaceuticals SWOT Analysis
Table 167. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 168. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 169. IO THERAPEUTICS Basic Information, Manufacturing Base and Competitors
Table 170. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Major Business
Table 171. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Total Revenue (USD Million) (2017-2018)
Table 172. IO THERAPEUTICS SWOT Analysis
Table 173. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product and Services
Table 174. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 175. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Manufacturer (2018-2019) (KG)
Table 176. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Manufacturer (2018-2019) (USD Million)
Table 177. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Regions (2015-2020) (KG)
Table 178. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Regions (2015-2020)
Table 179. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Regions (2015-2020) (USD Million)
Table 180. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Countries (2015-2020) (KG)
Table 181. North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Countries (2015-2020)
Table 182. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Countries (2015-2020) (USD Million)
Table 183. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Countries (2015-2020)
Table 184. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Countries (2015-2020) (KG)
Table 185. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Countries (2015-2020)
Table 186. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Countries (2015-2020) (USD Million)
Table 187. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Regions (2015-2020) (KG)
Table 188. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Regions (2015-2020)
Table 189. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Regions (2015-2020) (USD Million)
Table 190. South America Benign Prostatic Hyperplasia (BPH) Medication Sales by Countries (2015-2020) (KG)
Table 191. South America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Countries (2015-2020)
Table 192. South America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Countries (2015-2020) (USD Million)
Table 193. South America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Countries (2015-2020)
Table 194. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Countries (2015-2020) (KG)
Table 195. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Countries (2015-2020)
Table 196. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Countries (2015-2020) (USD Million)
Table 197. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Countries (2015-2020)
Table 198. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2015-2020) (KG)
Table 199. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Type (2015-2020)
Table 200. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2015-2020) (USD Million)
Table 201. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Type (2015-2020)
Table 202. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2015-2020) (KG)
Table 203. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Application (2015-2020)
Table 204. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Regions (2021-2025) (KG)
Table 205. Global Benign Prostatic Hyperplasia (BPH) Medication Market Share Forecast by Regions (2021-2025)
Table 206. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Type (2021-2025) (KG)
Table 207. Global Benign Prostatic Hyperplasia (BPH) Medication Market Share Forecast by Type (2021-2025)
Table 208. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Application (2021-2025)
Table 209. Global Benign Prostatic Hyperplasia (BPH) Medication Market Share Forecast by Application (2021-2025)
Table 210. Direct Channel Pros & Cons
Table 211. Indirect Channel Pros & Cons
Table 212. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Medication Picture
Figure 2. Global Sales Market Share of Benign Prostatic Hyperplasia (BPH) Medication by Type in 2019
Figure 3. 5-Alpha-Reductase Inhibitors Picture
Figure 4. Beta-Blockers Picture
Figure 5. Botanicals and Traditional Chinese Medicine Picture
Figure 6. Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application in 2018
Figure 7. Hospital Pharmacies Picture
Figure 8. Retail Pharmacies Picture
Figure 9. Online Pharmacies Picture
Figure 10. Global Benign Prostatic Hyperplasia (BPH) Medication Market Status and Outlook (2015-2025) (USD Million)
Figure 11. United States Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Canada Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Mexico Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Germany Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 15. France Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 16. UK Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Russia Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Italy Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 19. China Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Japan Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Korea Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 22. India Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Australia Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 25. Brazil Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Egypt Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 28. South Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Turkey Benign Prostatic Hyperplasia (BPH) Medication Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Manufacturer in 2019
Figure 31. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Manufacturer in 2019
Figure 32. Top 3 Benign Prostatic Hyperplasia (BPH) Medication Manufacturer (Revenue) Market Share in 2019
Figure 33. Top 6 Benign Prostatic Hyperplasia (BPH) Medication Manufacturer (Revenue) Market Share in 2019
Figure 34. Key Manufacturer Market Share Trend
Figure 35. Global Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 36. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Growth Rate (2015-2020) (USD Million)
Figure 37. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Regions (2015-2020)
Figure 38. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Regions in 2018
Figure 39. North America Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
Figure 40. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
Figure 42. South America Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
Figure 43. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
Figure 44. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue and Growth Rate (2015-2020) (USD Million)
Figure 45. North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Countries (2015-2020)
Figure 46. North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Countries in 2018
Figure 47. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 48. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Countries in 2018
Figure 49. United States Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 50. Canada Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 51. Mexico Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 52. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue and Growth Rate (2015-2020) (USD Million)
Figure 53. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Countries (2015-2020)
Figure 54. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Countries in 2019
Figure 55. Germany Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 56. UK Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 57. France Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 58. Russia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 59. Italy Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 60. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue and Growth Rate (2015-2020) (USD Million)
Figure 61. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Regions 2019
Figure 62. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Regions 2019
Figure 63. China Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 64. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 65. Korea Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 66. India Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 67. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 68. South America Benign Prostatic Hyperplasia (BPH) Medication Revenue and Growth Rate (2015-2020) (USD Million)
Figure 69. South America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Countries in 2019
Figure 70. South America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Countries in 2019
Figure 71. Brazil Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 72. Argentina Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 73. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue and Growth Rate (2015-2020) (USD Million)
Figure 74. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Countries in 2019
Figure 75. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Countries (2015-2020)
Figure 76. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Countries in 2019
Figure 77. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 78. Egypt Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 79. Turkey Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 80. South Africa Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020) (KG)
Figure 81. Global Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2021-2025) (KG)
Figure 82. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Growth Rate (2021-2025) (USD Million)
Figure 83. North America Sales Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025) (KG)
Figure 84. Europe Sales Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025) (KG)
Figure 85. Asia-Pacific Sales Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025) (KG)
Figure 86. South America Sales Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025) (KG)
Figure 87. Middle East & Africa Sales Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025) (KG)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
ドライアイ治療薬の世界市場 2020年 Market Overview The Dry Eye Medication market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tr…- 自動薬品ディスペンサーの世界市場 2020年 Market Overview The global Automatically Medication Dispenses market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Automatica…
- 精神医学的薬物療法の世界市場 2020年 Market Overview The global Psychiatric Medication Therapies market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Psychiatric …
- 自己投与薬剤の世界市場 2020年 Market Overview The global Self-Administered Medication market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Self-Administere…
- フレーバー獣医用医薬品の世界市場 2020年 Market Overview The global Flavored Veterinary Medication market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Flavored Veter…